Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease

被引:0
|
作者
Clara Antoury [1 ]
Rocio Lopez [2 ]
Nizar Zein [3 ]
James K Stoller [4 ]
Naim Alkhouri [3 ]
机构
[1] Department of Internal Medicine,Cleveland Clinic Foundation
[2] Department of Quantitative Health Sciences,Cleveland Clinic Foundation
[3] Department of Gastroenterology and Hepatology and Digestive Disease Institute,Cleveland Clinic Foundation
[4] Departments of Pulmonary and Critical Care,Respiratory Institute and Education Institute,Cleveland Clinic Foundation
关键词
Hepatocellular carcinoma; Liver cirrhosis; End-stage liver disease; Hepatitis C virus; Alpha-1 antitrypsin deficiency;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
AIM:To evaluate the association between alpha-1 antitrypsin deficiency(A1ATD) and hepatocellular carcinoma(HCC) in patients with end-stage liver disease(ESLD).METHODS:Patients with cirrhosis and ESLD referred to the Cleveland Clinic Foundation for liver transplantation between 2003 and 2014 were included in the study(N = 675). ESLD was defined as having histological features of cirrhosis and/or radiological evidence of cirrhosis in the context of portal hypertension(ascites,variceal bleeding,thrombocytopenia,or hepatic encephalopathy). A1 ATD was diagnosed using phenotype characterization(MZ or ZZ),liver biopsy detection of PAS-positive diastaseresistant(PAS+) globules,or both. Patients with other causes of liver diseases such as hepatitis C virus(HCV),alcoholic liver disease and non-alcoholic steatohepatitis(NASH) or NASH were also included in the study. HCC was diagnosed by using imaging modalities,biopsy findings,or explanted liver inspection. Follow-up time was defined as the number of years from the diagnosis of cirrhosis to the diagnosis of hepatocellular carcinoma,or from the diagnosis of cirrhosis to the last follow up visit. The rate of HCC was assessed using time-tointerval analysis for interval censored data.RESULTS:This study included 675 patients. 7% of subjects had A1ATD(n = 47). Out of all subjects who did not have A1 ATD,46% had HCV,17% had alcoholic liver disease,19% had NASH and 18% had another primary diagnosis. Of the 47 subjects with A1 ATD,15 had a primary diagnosis of A1ATD(PI*ZZ phenotype and PAS+ globules),8 had a PI*MZ phenotype alone,14 had PAS+ alone,and 10 had both the PI*MZ phenotype and PAS+. Median follow-up time was 3.4(25th,75 th percentiles:1,5.2) years. The overall rate of hepatocellular carcinoma in all subjects was 29%(n = 199). In the A1 ATD group,the incidence rate of HCC was 8.5% compared to 31% in the group of patients with other causes of cirrhosis(P = 0.001). Patients with ESLD due to A1 ATD had the lowest yearly cumulative rate of hepatocellular carcinoma at 0.88% per year compared to 2.7% for those with HCV cirrhosis,1.5% in patients with NASH and 0.9% in alcohol-induced liver disease(P < 0.001).CONCLUSION:Within this group of patients with ESLD,there was no significant association between A1 ATD and increased risk of HCC.
引用
收藏
页码:1427 / 1432
页数:6
相关论文
共 50 条
  • [21] THE LIMITATIONS OF SERUM ALPHA-1 ANTITRYPSIN LEVELS IN PATIENTS WITH CHRONIC LIVER DISEASE AND HETEROZYGOUS ALPHA-1 ANTITRYPSIN DEFICIENCY
    Mela, M.
    Smeeton, W.
    Alexander, G.
    GUT, 2011, 60
  • [22] MAN1B1 GENE VARIANTS AS A POTENTIAL CAUSE OF EARLY-ONSET END-STAGE LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY.
    Akepati, Prithvi Reddy
    Steinberg, Kate
    Kaserman, Joseph
    Wilson, Andrew
    Higgins, Michelle
    GASTROENTEROLOGY, 2020, 158 (06) : S1263 - S1263
  • [23] Liver cancer in severe alpha-1 antitrypsin deficiency: who is at risk?
    Fromme, Malin
    Strnad, Pavel
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60 (05)
  • [24] Paediatric liver transplantation for end-stage liver disease secondary to α1-antitrypsin deficiency.
    Francavilla, R
    Hadzic, N
    Chambers, S
    Castellaneta, SP
    Cheeseman, P
    Tung, J
    Rela, M
    Heaton, ND
    Mieli-Vergani, G
    HEPATOLOGY, 1998, 28 (04) : 357A - 357A
  • [25] Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
    McLean, Caitriona
    Greene, Catherine M.
    McElvaney, Noel G.
    BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 63 - 75
  • [26] SERUM ALPHA-1 ANTITRYPSIN DEFICIENCY AND INFANTILE LIVER-DISEASE
    FAVARA, BE
    FRANCIOS.RA
    SILVERMA.A
    PEDIATRIC RESEARCH, 1972, 6 (04) : 378 - &
  • [27] CONTRIBUTION OF GUT MICROBIOME TO ALPHA-1 ANTITRYPSIN DEFICIENCY LIVER DISEASE
    Kirst, Mariana
    West, Jesse
    Clark, Virginia C.
    Brantly, Mark
    HEPATOLOGY, 2019, 70 : 1164A - 1164A
  • [28] Cleaning up alpha-1 antitrypsin deficiency related liver disease
    Rademacher, Laura
    Fromme, Malin
    Strnad, Pavel
    CURRENT OPINION IN GASTROENTEROLOGY, 2023, 39 (03) : 163 - 168
  • [29] Liver Disease after Lung Transplant in Alpha-1 Antitrypsin Deficiency
    Vu, H. T.
    Zein, N. N.
    Murthy, S. C.
    Mason, D. P.
    Pettersson, G. B.
    Mehta, A. C.
    Budev, M. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [30] Airway Disease in Alpha-1 Antitrypsin Deficiency
    Strange, Charlie
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2013, 10 : 68 - 73